141 related articles for article (PubMed ID: 21525722)
1. Expression of ERĪ² and its co-regulators p300 and NCoR in human transitional cell bladder cancer.
Kontos S; Papatsoris A; Kominea A; Melachrinou M; Tanoglidi A; Kachrilas S; Karavitakis M; Balampani E; Sotiropoulou-Bonikou G
Urol Int; 2011; 87(2):151-8. PubMed ID: 21525722
[TBL] [Abstract][Full Text] [Related]
2. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].
Leng J; Zhang Y; Yao X; Wen K
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985
[TBL] [Abstract][Full Text] [Related]
3. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
4. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
5. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
King ED; Matteson J; Jacobs SC; Kyprianou N
J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
[TBL] [Abstract][Full Text] [Related]
6. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S
BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549
[TBL] [Abstract][Full Text] [Related]
7. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
8. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
10. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
11. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
[TBL] [Abstract][Full Text] [Related]
12. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer.
Yamanaka M; Kanda K; Li NC; Fukumori T; Oka N; Kanayama HO; Kagawa S
J Urol; 2001 Dec; 166(6):2495-9. PubMed ID: 11696817
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer.
Theodoropoulos VE; Lazaris ACh; Sofras F; Gerzelis I; Tsoukala V; Ghikonti I; Manikas K; Kastriotis I
Eur Urol; 2004 Aug; 46(2):200-8. PubMed ID: 15245814
[TBL] [Abstract][Full Text] [Related]
19. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
[TBL] [Abstract][Full Text] [Related]
20. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
